Key Findings
Lonza offers comprehensive, integrated development and manufacturing services for Antibody-Drug Conjugates (ADCs), spanning from clinical-stage development to commercial production. This end-to-end portfolio covers antibody production, cytotoxic payload synthesis, bioconjugation (linking the antibody and payload), and sterile fill and finish operations. The service aims to significantly accelerate ADC program timelines and reduce the inherent complexity associated with bringing these intricate bioconjugate therapeutics to market.
Technical / Clinical Details
ADCs are complex biologics that combine the specific targeting capabilities of antibodies with the potent cell-killing power of cytotoxic payloads. Their development and manufacturing require diverse expertise and specialized facilities. Lonza’s services seamlessly integrate the following key components:
- Antibody Manufacturing: Support for customer antibody candidates, from cell line development through large-scale GMP manufacturing.
- Payload Production: Synthesis of highly potent cytotoxic payloads at scales ranging from grams to multi-kilograms, conducted in specialized GMP production suites at Lonza’s Visp, Switzerland site. These payloads are manufactured under stringent quality control.
- Bioconjugation: Provision of technologies to stably and efficiently link the developed payloads to antibodies. This includes optimization of linker types and conjugation sites to maximize the therapeutic index of the ADC.
- Final Formulation and Sterile Fill & Finish: Ensuring the stability of the conjugated ADC formulation and providing aseptic filling and finishing processes in controlled environments.
Lonza’s Visp site is equipped with state-of-the-art facilities and technologies to safely and efficiently handle these activities, including advanced containment strategies for highly potent payloads and conjugates.
Background & Context
The Antibody-Drug Conjugate market is one of the most dynamically growing segments in pharmaceuticals, with established efficacy across multiple cancer types. However, ADC development and manufacturing present significant hurdles compared to traditional biologics or small molecule drugs due to their inherent complexity. The expertise required for antibodies, linkers, and payloads, and the necessity to integrate these distinct manufacturing processes, often make in-house production challenging for many pharmaceutical companies. Lonza’s comprehensive ‘end-to-end’ services enable pharmaceutical companies to focus their resources on R&D while ensuring efficient development and manufacturing of high-quality ADCs. This approach effectively de-risks development and shortens time-to-market.
Strategic Significance & Outlook
Lonza’s integrated ADC manufacturing services are poised to play a crucial role in the continuously expanding ADC market. ADCs are expected to broaden their applicability further through target diversification, payload evolution, and the introduction of dual-payload technologies. CDMOs like Lonza will support customers in developing and manufacturing cutting-edge ADCs by adapting to these technological innovations, thereby expanding the frontiers of drug development. Ultimately, these services contribute to bringing innovative, life-saving cancer treatments to more patients faster. Investors are keenly interested in the growth of the ADC market and the capabilities of key CDMOs supporting this growth.
Source: https://www.lonza.com/advanced-synthesis/bioconjugates/adc-clinical-and-commercial-manufacturing
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments